ACE2 News and Research

RSS

Novel receptor protein may hold promise for treating COVID-19

A novel receptor protein that binds to the SARS-CoV-2 virus and prevents it from entering cells may hold promise for treating COVID-19 and other coronavirus-related diseases, according to research published online Aug. 4 in the journal SCIENCE.

17 Aug 2020

SARS-CoV-2 poses significant threat to many marine mammal species

A new study conducted by researchers at Dalhousie University in Halifax, Canada, has found that many species of marine mammal are highly vulnerable to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

17 Aug 2020

Scientists claim signs of lasting SARS-CoV-2 immunity

Questions have been raised by many health experts on whether being infected with SARS-CoV-2 brings lasting immunity. Now, scientists have uncovered signs of strong and lasting immunity in people who even had a mild illness of COVID-19.

17 Aug 2020

Coronacept - A trap-and-destroy molecule against SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 reports a novel engineered molecule based on human and other mammalian orthologues of ACE2 fused with the Fc part of the antibody. This molecule interacts more tightly with the viral receptor-binding domain (RBD) to constitute a powerful immunoadhesin that targets the virus for destruction.

17 Aug 2020

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

ARDS may not be the primary lung iInjury in COVID-19

A new Italian study published on the preprint server medRxiv in August 2020 shows that this may not be an adequate explanation, since ARDS is a nonspecific diagnosis. Instead, they say, antemortem lung biopsy shows a “Covid pattern” of acute lung injury, which could guide the application of therapeutics.

16 Aug 2020

SARS-CoV-2 spike pocket is a putative target for antiviral design

In a methodologically rigorous study, researchers from the University of Oxford have recently shown how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein harbors a lipid-binding pocket which modulates the stability of the prefusion trimer and provides conformational shielding from antibodies. Their findings are currently freely available on the bioRxiv* preprint server.

16 Aug 2020

Preexisting drug shows promise as a weapon against SARS-CoV-2 virus

First appearing in late 2019 in Wuhan City, China, the SARS-CoV-2 virus continues to cause sickness and death across the globe.

14 Aug 2020

COVID-19 during pregnancy shows no affect on placental structure and pathology

A new study published on the preprint server medRxiv in August 2020 shows that the placenta in pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) does not show any signs of abnormality that can be attributed to the infection.

14 Aug 2020

De novo designed SARS-CoV-2 nanoparticle vaccine

In light of the continuing threat to public health, social functioning, and economic activity posed by the COVID-19 pandemic, scientists are working urgently to bring out a vaccine that is both safe and effective, and capable of mass production. A new paper published on the preprint server bioRxiv* in August 2020 shows that such a vaccine may be produced by using arrays of one severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein on a nanoparticle platform.

14 Aug 2020

Experimental COVID-19 vaccine prevents severe disease in mice

Now, a novel experimental vaccine that is made from a mild virus genetically-modified to carry an essential gene from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronary disease (COVID-19), has shown promise in preventing pneumonia in mice infected with the virus.

14 Aug 2020

Membrane nanoparticles acts as a bait to trap SARS-CoV-2

In an exciting new bioRxiv preprint research paper, Chinese researchers describe the development of membrane nanoparticles from ACE2-rich cells with a potent capacity to block the adherence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

13 Aug 2020

Synthetic nanobodies prevent SARS-CoV-2 infection

A team of researchers from the University of California San Francisco has created a powerful nasal spray or inhaler that can provide high-grade protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The report is presently available on the bioRvix* preprint server.

13 Aug 2020

Cardiovascular disease in COVID-19

The current COVID-19 pandemic is a primarily respiratory illness, manifesting with severe hypoxia and often progressing to acute respiratory distress syndrome (ARDS) and death. However, it is also known to be linked to a wide range of cardiovascular (CV) manifestations that are associated with a very poor prognosis.

13 Aug 2020

C-type lectin receptors play a role in SARS-CoV-2 infection

A new study published on the preprint server bioRxiv in August 2020 confirms and extends earlier findings showing that a type of sugar-based receptor on innate immune cells promotes the entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into other cells that carry the viral receptor, angiotensin-converting enzyme 2 (ACE2).

12 Aug 2020

Study reveals new clues about SARS-CoV-2 infection

Working together, researchers at McMaster University and the University of Waterloo are searching for how the SARS-CoV-2 virus infects the lungs - and they're challenging what has become an accepted truth about the virus.

12 Aug 2020

Research looks at convalescent plasma use in COVID-19 mouse model

A new study by researchers at the University of Iowa and published on the preprint server bioRxiv in August 2020 reports the utility of a mouse model that recapitulates several aspects of human COVID-19 and can reflect the antiviral efficacy of new drugs as well.

12 Aug 2020

SARS-CoV-2 a "swarm" of mutant viruses

In this new study, the virus was serially passaged in independent cell types in a controlled environment. The researchers found that the virus rapidly adapts to the changing conditions in culture by selecting for pre-existing species.

12 Aug 2020

Scientist explains why COVID-19 targets only some organs while others are spared

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the enzyme angiotensin-converting enzyme 2 (ACE2) to enter and infect human cells. It causes COVID-19 and can lead to a multitude of complications, including multi-organ impairment, partially due to the abundant expression of ACE2 in all human tissues.

11 Aug 2020

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

A recent study by researchers from China, available on the bioRxiv preprint server, shows how stable neutralizing nanobody Nb11-59 might be a promising prophylactic and therapeutic molecule against coronavirus disease (COVID-19) – especially if administered via the inhalatory route.

11 Aug 2020